Exhibit 99.1

                                                COMPANY CONTACT:

                                                Cindy Presar, Investor Relations
                                                cpresar@cardiodynamics.com
                                                800-778-4825 Ext. 1031

                      CARDIODYNAMICS ANNOUNCES PUBLICATION
                    OF MULTICENTER HYPERTENSION CONTROL TRIAL

        PUBLISHED IN HYPERTENSION, AN AMERICAN HEART ASSOCIATION JOURNAL

SAN DIEGO--March 7, 2006--CardioDynamics (Nasdaq: CDIC), the innovator and
leader of impedance cardiography (ICG) technology, today announced the
publication of its multicenter, randomized trial called CONTROL (Consideration
Of Noninvasive Hemodynamic Monitoring To Target Reduction Of Blood Pressure
Levels). The article was published online in Hypertension, an American Heart
Association journal, and the print version of the article will appear in the
April edition of the journal. The study demonstrated that using the Company's
BioZ(R) ICG to make drug decisions achieved 35% superiority in blood pressure
control to less than 140/90 millimeters of mercury (mm Hg) as compared to the
standard treatment group.

Family practice and internal medicine physicians from 11 centers followed 164
patients on one or more antihypertensive medications over five visits in a three
and one-half month period. Patients in the BioZ group had 8 mm Hg greater
systolic blood pressure reduction and 7 mm Hg greater diastolic blood pressure
reduction than those in the standard care group. In addition to the BioZ group
achieving a 35% improvement in blood pressure control to less than 140/90 mm Hg
as compared to the standard care group, there was more than double the
improvement in aggressive blood pressure control to less than 130/85 mm Hg.



"The CONTROL trial represents the most significant data ever published on our
noninvasive BioZ ICG technology," stated Michael K. Perry, CardioDynamics' Chief
Executive Officer. "The results of the trial clearly illustrate the significance
of our BioZ technology in the treatment of mild to moderate high blood pressure,
which is the most common reason patients in our country visit their physicians.
The CONTROL trial results, along with the previous trial results from the Mayo
Clinic involving more severe hypertension patients on a greater number of
medications, are strong evidence that use of ICG improves outcomes in this
costly disease. We believe these two trials are the primary evidence that
Medicare will evaluate in their review of whether to expand hypertension
coverage for BioZ ICG."

Over 65 million patients in the United States and one billion worldwide have
high blood pressure. Only about one-third of hypertension patients have
controlled blood pressure, and uncontrolled hypertension is a significant risk
factor for stroke, heart attacks, heart failure, and kidney disease. High blood
pressure is caused by either high blood flow (cardiac output) or high resistance
in the vessels (systemic vascular resistance), and hypertensive drugs reduce
blood pressure by reducing cardiac output or systemic vascular resistance.
Physicians are unable to assess these parameters without invasive or expensive
methods, but BioZ ICG noninvasively and inexpensively measures both of these
parameters.

Carlos Ferrario, M.D., Professor and Director, Hypertension and Vascular Disease
Center, Wake Forest University School of Medicine, Winston-Salem, NC, a
principal investigator of the study and prominent hypertension researcher,
concluded, "There is an urgent need to improve our treatment of hypertension.
The CONTROL trial showed that hypertensive patients in the BioZ group achieved
significantly better blood pressure outcomes than the standard care group. New
drugs for hypertension are judged favorably by the Food Drug Administration and
medical community when they reduce blood pressure less than half as much as that
achieved in the arm of the study which employed the BioZ to tailor
antihypertensive therapy. Using the BioZ to treat hypertension could
significantly improve blood pressure control in the United States, given our
current lack of success and the known challenges that physicians treating
hypertension face in their practice."



The Company also noted that an accompanying editorial to the CONTROL trial was
also published in Hypertension. The editorial offered encouragement for the use
of ICG in the physician office based on its ability to improve the chances for
successful blood pressure control through better drug decision making. The
editorial also stated that ICG may be one of several advances that will drive a
new trend toward individualizing hypertension treatment for each patient.

ABOUT CARDIODYNAMICS:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
an important medical technology called impedance cardiography (ICG). The Company
develops, manufactures and markets noninvasive ICG products and medical device
electrodes. The Company's ICG Systems are being used by physicians around the
world to help battle the number one killer of men and women--cardiovascular
disease. Partners include GE Healthcare and Philips Medical Systems. For
additional information, please refer to the company's Web site at www.cdic.com.

FORWARD-LOOKING (SAFE HARBOR) STATEMENT:

Except for the historical and factual information contained herein, this press
release contains forward-looking statements, such as what evidence Medicare uses
in its review of whether to expand hypertension coverage for BioZ ICG, the
accuracy of which is necessarily subject to uncertainties and risks including
the Company's sole dependence on the BioZ product line, and various
uncertainties characteristic of early growth companies, as well as other risks
detailed in the Company's filings with the SEC, including its 2005 Form 10-K.
The Company does not undertake to update the disclosures contained in this press
release.